{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+to+Severe+Plaque-type+Psoriasis&page=3", "query": { "condition": "Moderate to Severe Plaque-type Psoriasis", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+to+Severe+Plaque-type+Psoriasis&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+to+Severe+Plaque-type+Psoriasis&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T18:41:39.634Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02690701", "title": "Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Plaque Psoriasis" ], "interventions": [ { "name": "Secukinumab 300 mg", "type": "DRUG" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2016-02-10", "completion_date": "2018-02-19", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-10-21T18:41:39.634Z", "location_count": 12, "location_summary": "Los Angeles, California • Santa Ana, California • Rockville, Maryland + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Rockville", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02690701" }, { "nct_id": "NCT02203032", "title": "A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" }, { "name": "Placebo for ustekinumab", "type": "DRUG" }, { "name": "Placebo for guselkumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 872, "start_date": "2014-10-07", "completion_date": "2016-05-24", "has_results": true, "last_update_posted_date": "2017-09-12", "last_synced_at": "2026-10-21T18:41:39.634Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02203032" }, { "nct_id": "NCT00800982", "title": "Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Narrow band (310-312 nm) ultraviolet light B phototherapy", "type": "PROCEDURE" }, { "name": "etanercept", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-10", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2013-05-07", "last_synced_at": "2026-10-21T18:41:39.634Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00800982" }, { "nct_id": "NCT02502188", "title": "Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Parapsoriasis", "Healthy Volunteers" ], "interventions": [ { "name": "CC-90005", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2015-07-17", "completion_date": "2015-11-02", "has_results": false, "last_update_posted_date": "2019-11-18", "last_synced_at": "2026-10-21T18:41:39.634Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02502188" }, { "nct_id": "NCT01490632", "title": "A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis", "Skin Diseases", "Skin Diseases, Papulosquamous" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 271, "start_date": "2011-12", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2019-09-27", "last_synced_at": "2026-10-21T18:41:39.634Z", "location_count": 18, "location_summary": "Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miramar", "state": "Florida" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490632" }, { "nct_id": "NCT02622386", "title": "The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Riboflavin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2016-08-11", "completion_date": "2020-04-06", "has_results": true, "last_update_posted_date": "2022-07-28", "last_synced_at": "2026-10-21T18:41:39.634Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02622386" }, { "nct_id": "NCT01690299", "title": "Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis", "Psoriatic Arthritis" ], "interventions": [ { "name": "Apremilast", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Placebo tablet", "type": "DRUG" }, { "name": "Placebo injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2012-10-01", "completion_date": "2016-04-04", "has_results": true, "last_update_posted_date": "2022-03-15", "last_synced_at": "2026-10-21T18:41:39.634Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01690299" }, { "nct_id": "NCT01483599", "title": "A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "CNTO 1959 (5 mg)", "type": "DRUG" }, { "name": "CNTO 1959 (15 mg)", "type": "DRUG" }, { "name": "CNTO 1959 (50 mg)", "type": "DRUG" }, { "name": "CNTO 1959 (100 mg)", "type": "DRUG" }, { "name": "CNTO 1959 (200 mg)", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 293, "start_date": "2011-11-10", "completion_date": "2013-08-05", "has_results": true, "last_update_posted_date": "2017-08-02", "last_synced_at": "2026-10-21T18:41:39.634Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01483599" }, { "nct_id": "NCT00655564", "title": "Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Alefacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2008-05", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2018-09-11", "last_synced_at": "2026-10-21T18:41:39.634Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00655564" }, { "nct_id": "NCT01406938", "title": "Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Plaque-type Psoriasis" ], "interventions": [ { "name": "AIN457 150mg", "type": "DRUG" }, { "name": "AIN457 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 967, "start_date": "2011-08", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-05-19", "last_synced_at": "2026-10-21T18:41:39.634Z", "location_count": 33, "location_summary": "Fresno, California • Pasadena, California • Sacramento, California + 28 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01406938" } ] }